The most commonly used prognostic parameters in untreated patients are histological grade, T category of the primary tumour as defined by UICC (UICC, 1978) , extent of metastatic tumour burden, serum testosterone level and serum prostate specific antigen level (PSA) . In hormone resistant prostatic cancer, factors such as the patient's performance status and serum alkaline phosphatase level seem to be of prognostic significance (Berry et al., 1979; Mulders et al., 1990; Matzkin et al., 1992) .
Immunohistochemical demonstration of neuroendocrine differentiation (di Sant 'Agnese & de Mesy Jensen, 1987; Cohen et al., 1991) , c-erbB-2 protein (Gullick et al., 1991; Reilly et al., 1991; Hale et al., 1992) , p53 protein (Porter et al., 1992) and PSA (Hammond et al., 1989; Bazinet et al., 1992) have also been related to tumour growth.
In order to increase our understanding of the biological changes associated with the development of therapy resistance, we examined some of the above mentioned parameters in prostatic cancer specimens obtained before hormone treatment and in comparable specimens achieved when the patient had developed a hormone resistant malignancy.
Material and methods

Clinical material
Forty-seven patients with prostatic cancer were identified in whom at least one tissue specimen had been obtained before start of hormone treatment and one biopsy when the tumour had progressed despite androgen suppressive therapy, achieved either by surgical or medical castration. Patient details are shown in Table I Gleason's (Gleason, 1974) and WHO's (Mostofi et al., 1980) classification systems. Gleason grades were grouped as follows: grades 2-4 (group 1), grades 5-7 (group 2) and grades 8-10 (group 3). Immunohistochemistry Paraffin-embedded material was prepared by applying the avidin-biotin-peroxidase complex (ABC) method (Hsu et al., 1981) . After removal of paraffin, the sections were treated for 30min with 0.3% hydrogen peroxide in methanol to block endogenous peroxidase, followed by 20 min incubation with non-reactive serum diluted 1:75 om 0.01 M phosphate buffered saline (pH 7.4) containing 5% bovine serum albumin (BSA) to eliminate non-specific staining. The sections were then incubated at 4°C overnight with the primary antibodies raised against c-erbB-2 protein (monoclonal antibody diluted 1:40 (NCL CB1 1 Novocastra, UK)), NSE (monoclonal antibody diluted 1:700 (Dakopatts)), p53 protein (Polyclonal antibody diluted 1:300 (Novocastra)) and PSA (monoclonal The immunostained sections were examined independently by two pathologists (A.B., J.M.N.). Localisation of the immunostaining in relation to cellular morphology was noted, and the fraction of immunoreactive tumour cells was semiquantitatively graded from 0 to + + + in each section.
Control studies included relevant positive controls, the use of IgG of the same fraction as the primary antibody or non-reactive serum as first layer. The immunoreactivity was checked with an absorption control adding antigen to the primary antibody prior to incubation. All controls gave satisfactory results.
Statistics
All statistical calculations were performed in the PC program 'Medlog'. The following tests were used: Fisher exact probability test, Chi-squared test. The probability of survival was calculated by the Kaplan Meyer method and survival differences were assessed by the log rank test. P-values <0.05 were regarded as statistically significant.
Results
Grade
Using both the Gleason and the WHO grading system, significantly more specimens with a high histological grade were found among the post-treatment specimens than among the pre-treatment biopsies (Gleason: P<0.0001, WHO: P:0.003) (Table II) . In 22 of the 47 patients the tumour was more undifferentiated in post-treatment specimens (Table  IIIa) , while the tumour grade remained unchanged in 25 patients including the ten patients with Gleason grade 8-10 at the time of diagnosis. Undifferentiated carcinomas as defined by the WHO system were not seen. Twenty patients expressed less PSA reactivity in the posttreatment specimens. The reactivity remained the same in 25 specimens, and only one expressed more PSA (Table III) . The difference was statistically significant (P:0.011). (Catalona et al., 1982; Lange & Narayan, 1983) in small biopsies. However, only 17 of the 94 specimens in our study were core biopsies.
A fundamental assumption by Gleason (Gleason, 1977) was that morphologic grade and growth rate of prostatic cancer remained unaltered throughout the patient's lifespan. However, this has been contradicted by Brawn and others (Brawn, 1983; McNeal et al., 1986; MacNeal et al., 1988a) . coworkers (1986, 1988a ) examined prostatectomy specimens whereas Brawn (1983) graded repeat TUR biopsies and found that 65% of his patients showed a higher malignancy grade with time. Gleason did only include some occasional re-biopsies in his study. In their studies, Lundberg and associates (1987) , Epstein and coworkers (1986) and deVere White et al. (1990) and others also used only one tissue specimen from the individual patient and thus limiting the validity of these investigations. In our study we have evaluated pre-and post-treatment specimens from the same patient, and, like Brawn, we found more often less differentiated tumour tissue in the repeat specimens. p53 is a suppressor gene which participates in cell cycle regulation and growth control (Levine et al., 1991) . Most investigators agree that accumulation of p53 protein to levels detectable by immunohistochemical methods is caused by an underlying genetic lesion, most frequently point mutation on chromosome 17, although stabilisation of wild type p53 protein has been postulated (Wynford-Thomas, 1992). The widespread occurrence of p53 gene mutations in different types of tumours suggests that p53 mutation participates in the neoplastic transformation of most types of human neoplasia (Porter et al., 1992) . The biological significance of p53 protein overexpression is not established, but most authors agree that p53 protein expression arises relatively late in neoplastic progression and may correlate with increased tumour aggressiveness (Porter et al., 1992; Sawan et al., 1992) . Isaacs and coworkers (Isaacs et al., 1991) reported p53 mutations in prostatic cancer cell lines and one p53 gene mutation has recently been reported in human prostatic cancer tissue (Effert et al., 1992) . Mellon and coworkers (Mellon et al., 1992 ) noticed p53 protein expression in five out of 29 poorly differentiated prostatic carcinomas. This is in agreement with our findings. In addition, we observed increased p53 protein immunoreactivity with progression of the disease (P:0.006), but the p53 protein staining did not significantly correlate with any other parameters. Thus, increased p53 protein expression may be a parameter which rather independently mirrors tumour progression.
Prostate specific antigen (PSA) is produced both in benign and in malignant prostatic epithelium, and serum PSA is widely used as a tumour marker, correlating with tumour stage and response to treatment (Stamey et al., 1987) . In contrast to benign epithelium, most reports on prostatic cancer tissue demonstrate heterogeneity in immunostaining and an apparent correlation between variation in PSA stainability and tumour grade (Hammond et al., 1989; Epstein & Eggleston, 1984; Feiner & Gonzales, 1986) . Reduced PSA immunoreactivity has been noticed in prostatic intraepithelial neoplasia (McNeal et al., 1988b) . In a study of preand post-treatment prostatic carcinomas, Vernon and Williams (Vernon & Williams, 1983) found persistent PSA staining in all biopsies from 30 patients despite morphological changes with time, while Grignon and Troster (Grignon & Troster, 1985) reported reduced PSA reactivity in prostate cancer specimens from five out of 11 hormonally treated patients. Qiu and associates (Qiu et al., 1990 ) demonstrated a significant decrease in PSA mRNA expression in carcinoma tissue when compared with benign prostatic epithelium. Reduced PSA concentrations have also been found in carcinoma tissue by biochemical methods (Stege et al., 1990; Pretlow et al., 1991; Stege et al., 1992) . This is in agreement with our findings. Like Grignon and Troster (1985) but contrary to Vernon and Williams (1983) , we noticed a significant decrease in PSA staining in post-treatment specimens (P:0.01).
In our series the tissue stainability for PSA did not correlate with the individual patients serum PSA. This has also been noticed by Ersev and coworkers (Ersev et al., 1990) . One possible explanation may be that the PSA reactivity in tissues is often focal and small biopsies do not reflect the average PSA expression. Furthermore, there may be large inter-patient variations in PSA release from the cancer cells and/or a possible increase in PSA diffusion through abnormal blood vessels, which may explain decreased PSA tissue concentrations in spite of high serum levels (Stege et al., 1990; Prethlow et al., 1991) . Such discrepancies may change with time and during hormone treatment (Matzkin et al., 1992) .
Approximately 50% of prostatic cancers contain small numbers of neuro-endocrine cells (di Sant' Agnese & de Mesy Jensen, 1987; Cohen et al., 1991) and it has been suggested that neuro-endocrine differentiation is associated with poor prognosis, which was not confirmed in our study. However, contrary to di Sant'Agnese and de Mesy Jensen (1987) who used a battery of different neuro-endocrine markers and Cohen and coworkers (1991) who used polyclonal NSE antibody and monoclonal chromogranin antibody, we used only one monoclonal antibody raised against NSE, which may explain the lower scoring rate (32%) in our series. Neuroendocrine differentiation is mostly focal and Cohen and coworkers (1991) demonstrated that a single needle biopsy may be inadequate in demonstrating neuro-endocrine differentiation.
Although c-erbB-2 gene amplification has been documented in many different tumours, only a few studies have been performed on prostatic cancer tissue (McCann et al., 1990; Ware et al., 1991; Mellon et al., 1992) . Like McCann and associates (1990), we did not observe c-erbB-2 protein expression in formalin fixed prostatic cancer tissue. Both Ware and associates (1991) and Mellon and coworkers (1992) used fresh material and found c-erbB-2 protein expression in 71% and in 21%, respectively. Ware and associates also compared formalin fixed and fresh material and found that formalin fixation significantly reduced the c-erbB-2 protein immunoreactivity. This is also in agreement with Wright and coworkers observation in bladder tumours (Wright et al., 1990) .
We conclude that prostatic carcinoma showed a significantly dedifferentiation when the malignancy became hormone resistant. These changes are associated with increased p53 protein expression and decreased PSA immunoreactivity.
